USPTO published patent application US20260092071A1 covering compounds of Formula II and their pharmaceutical acceptable salts, solvates, or stereoisomers as SMARCA2 or SMARCA4 degraders. The application includes claims for compositions and methods of use. CPC classifications indicate applications in heterocyclic compounds (C07D 487/10, C07D 487/04), pharmaceutical preparations (A61K 31/519, A61K 31/527), with filing date September 22, 2023 under Application No. 19112750.\n\nThis is an informational publication of a patent application; no compliance actions, deadlines, or penalties apply. Companies developing targeted protein degradation therapies or SMARCA2/4 inhibitors should monitor this application for potential freedom-to-operate considerations. The published application provides public notice but does not yet grant patent rights.